SCHEMBL1099310

SCHEMBL1099310

COC(=O)c1ccc(CN(c2cc3ccccc3s2)S(=O)(=O)c2cccnc2)cc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.52
ALDH1A1 P00352 1/20 0.52
PTGER2 P43116 5/20 0.46
LMNA P02545 1/20 0.43
HTT P42858 1/20 0.43
NPSR1 Q6W5P4 1/20 0.43
PSEN1 P49768 1/20 0.43
PSEN2 P49810 1/20 0.43
APH1B Q8WW43 1/20 0.43
NCSTN Q92542 1/20 0.43
APH1A Q96BI3 1/20 0.43
PSENEN Q9NZ42 1/20 0.43
RAB9A P51151 4/20 0.42
NPC1 O15118 2/20 0.42
MAPT P10636 1/20 0.42
TRPM8 Q7Z2W7 2/20 0.41
CYP11B1 P15538 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
POLB P06746 1/20 0.40
KEAP1 Q14145 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1099070 0.91 PTGER2 (0.46) KDM4EALDH1A1PTGER2LMNAHTT
SCHEMBL18422594 0.81 ALDH1A1 (0.64) KDM4EALDH1A1LMNAHTTNPSR1
SCHEMBL1098142 0.80 KDM4E (0.51) KDM4EALDH1A1LMNAHTTNPSR1
SCHEMBL1097657 0.80 PTGER2 (0.43) PTGER2LMNAHTTNPSR1TRPM8
SCHEMBL1098953 0.79 NR1D1 (0.47) ALDH1A1PTGER2LMNAHTTNPSR1
SCHEMBL1098334 0.77 TRPM8 (0.58) KDM4EALDH1A1PSEN1PSEN2APH1B
SCHEMBL18423615 0.77 PSEN1 (0.54) KDM4EALDH1A1PTGER2LMNAHTT
SCHEMBL1098430 0.76 L3MBTL1 (0.47) KDM4EALDH1A1LMNAHTTPSEN1
SCHEMBL15948196 0.76 PKM (0.51) KDM4EALDH1A1PTGER2LMNAHTT
SCHEMBL1098832 0.76 PTGER2 (0.43) PTGER2MAPTTRPM8L3MBTL1KEAP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9434711-B2 Sulfonamides as TRPM8 modulators JANSSEN PHARMACEUTICA, N.V. (BE) 2016-09-06 US disclosed
US-20140315899-A1 SULFONAMIDES AS TRPM8 MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2014-10-23 US disclosed
US-8809327-B2 Sulfonamides as TRPM8 modulators JANSSEN PHARMACEUTICA, NV (BE) 2014-08-19 US disclosed
EP-2183239-B1 SULFONAMIDES AS TRPM8 MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2012-08-22 EP disclosed
US-8153682-B2 Sulfonamides as TRPM8 modulators JANSSEN PHARMACEUTICA, NV (BE) 2012-04-10 US disclosed
US-20090264474-A1 SULFONAMIDES AS TRPM8 MODULATORS JANSSEN PHARMACEUTICA, N.V. (BE) 2009-10-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140315899-A1 SULFONAMIDES AS TRPM8 MODULATORS TRPM8, TRPM5, TRPM2 KDM4E 3266/4885ALDH1A1 3091/4885PTGER2 297/4885
US-20090264474-A1 SULFONAMIDES AS TRPM8 MODULATORS TRPM8, TRPM5, TRPM2 KDM4E 3266/4885ALDH1A1 3091/4885PTGER2 297/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.